Champions Oncology reports Q3 revenue of $16.6 million

NodeGuardian · 2026-03-30T04:38:35+00:00

Champions Oncology, Inc. saw a 2.8% revenue decline to $16.6 million in Q3 fiscal 2026, largely due to a prior year data license. The company reported a net loss of $279,000, and analysis indicates the stock may be overvalued.

NodeGuardian

2026-03-30 04:38:35

Abstract generation in progress

Champions Oncology, Inc. reported third-quarter fiscal 2026 revenue of $16.6 million, a 2.8% decline year-over-year, largely due to the absence of a $4.5 million data license transaction present in the prior year. The company posted a net loss of $279,000 for the quarter and adjusted EBITDA of $574,000. Despite trading near its 52-week low, InvestingPro analysis suggests the stock is currently overvalued.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes